Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
August 1, 2023
Prophylactic use reduced annualized bleeding in hemophilia A and B pts with inhibitors. Concizumab is an anti–tissue factor pathway inhibitor monoclonal antibody.